Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta


Boz C. , Ozmenoglu M., Velioglu S. , Kilinc K., Orem A., Alioglu Z., ...Daha Fazla

CLINICAL NEUROLOGY AND NEUROSURGERY, cilt.108, ss.124-128, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 108 Konu: 2
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1016/j.clineuro.2005.01.005
  • Dergi Adı: CLINICAL NEUROLOGY AND NEUROSURGERY
  • Sayfa Sayıları: ss.124-128

Özet

Objectives: Matrix metalloproteinases (MMPs), particularly MMP-9, facilitate T-cell migration into the central nervous system. They play a key role in the disruption of the blood-brain barrier (BBB) and thus in the pathogenesis of multiple sclerosis. Interferon beta's (IFN beta) ability to alter the balance between MMP-9 and MMP-9s natural inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), may play a role in stabilizing the BBB. The aim of this study, was to evaluate serum MMP-9 and TIMP-1 and cerebrospinal fluid (CSF) TIMP-1 levels in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFN beta-1a.